One of the most promising antiangiogenic treatments is the anti-VEGF monoclonal antibody (mAb) bevacizumab (also known as rhuMAb-VEGF and marketed as Avastin ® by Genentech Inc., South San ...

Antiangiogenesis, heralded a while ago as the "magic bullet" to stop cancer growth, has lately entered a reconsideration phase. Results obtained in phase 1 through 3 clinical trials with different ...